Acetylcysteine: Clinical Trials

301 completed, 83 unknown, 39 terminated, 32 recruiting. 179 Phase 2, 99 Not applicable, 96 Phase 3, 86 Phase 4, 77 Phase 1.

By phase and status

Phase	Trials	Status
Phase 2	179	Completed 118, Unknown 18, Recruiting 14, Terminated 11, Active not recruiting 8, Withdrawn 4, Not yet recruiting 3, Enrolling by invitation 2, Suspended 1
Not applicable	99	Completed 58, Unknown 21, Terminated 6, Recruiting 5, Active not recruiting 2, Enrolling by invitation 2, Not yet recruiting 2, Withdrawn 2, Suspended 1
Phase 3	96	Completed 44, Unknown 23, Terminated 9, Active not recruiting 7, Not yet recruiting 6, Recruiting 4, Withdrawn 2, Enrolling by invitation 1
Phase 4	86	Completed 41, Unknown 21, Terminated 8, Recruiting 7, Not yet recruiting 3, Withdrawn 3, Active not recruiting 2, Suspended 1
Phase 1	77	Completed 54, Unknown 8, Terminated 5, Recruiting 4, Not yet recruiting 2, Withdrawn 2, Active not recruiting 1, Suspended 1
Early Phase 1	33	Completed 18, Terminated 5, Active not recruiting 3, Recruiting 2, Unknown 2, Withdrawn 2, Not yet recruiting 1

Follow Acetylcysteine: new trials by email Literature Review of Acetylcysteine trials Research Report on Acetylcysteine

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
The MIND Study: The MGH/MIT Investigation of NAC on Dysregulation N-Acetyl Cysteine (NAC), Placebo - Emotional Dysregulation	Early Phase 1	Not yet recruiting	Massachusetts General Hospital	120	2027-01-01	2026-04-17
Use of N-Acetylcysteine in the Treatment of Repetitive and Self-Injurious Behaviors in Cornelia de Lange Syndrome N-acetyl cysteine, Placebo - Cornelia de Lange Syndrome	Phase 2	Not yet recruiting	Johns Hopkins University	10	2026-11-01	2026-08-14
Therapeutics for Moderate and Severe Dengue Placebo, Dexamethasone, N-Acetylcysteine - Dengue, Severe Dengue	Phase 3	Not yet recruiting	Oxford University Clinical Research Unit, Vietnam	8800	2026-10-01	2026-04-21
NAC for Hematopoietic Recovery in Low/Intermediate-Risk AML After CR: A Randomized Controlled Study N-acetyl-L-cysteine (NAC) - Acute Myeloid Leukemia, Adult	Not applicable	Not yet recruiting	Peking University People's Hospital	180	2026-10-01	2026-10-09
Tolerability of Enteral NAC in Infants N-Acetylcysteine - Biliary Atresia	Phase 1	Not yet recruiting	Sanjiv Harpavat	12	2026-10-01	2026-03-04
Study to Evaluate the Effects of Oral Glyceryl Guiacolate (Guaifenesin, GGE) on Sputum Rheology in Subjects With Mucus Hypersecretion Glycerol Guiacolate, SOC (Standard of care) - Bronchitis, Bronchitis, Chronic	Phase 4	Not yet recruiting	University of North Carolina, Chapel Hill	40	2026-10-01	2026-10-14
Prophylactic NAC to Improve Platelet Engraftment After Haploidentical Transplantation in Severe Aplastic Anemia Patients N-acetylcysteine - Aplastic Anemia	Phase 3	Not yet recruiting	Peking University People's Hospital	142	2026-09-30	2026-09-16
Individualized Multiplex Pathophysiological Treatment of Severe Acute Infections: N-Acetylcysteine N-Acetylcysteine (NAC) Treatment - Sepsis, Acute Infection	Phase 4	Recruiting	Theis S. Itenov	360	2026-09-07	2026-09-16
Combination Therapy of Deferiprone and N-Acetylcysteine for Treating Negative Symptoms in Schizophrenia Deferiprone (DFP), N-Acetyl Cysteine (NAC) - Schizoaffecitve Disorder, Schizophrenia and Schizoaffective Disorder	Phase 2	Recruiting	Amit Lotan	80	2026-08-12	2026-09-29
Role of N-Acetylcysteine in Non-Acetaminophen-Induced Liver Failure N Acetyl Cysteine, Standard supportive care - Acute Liver Failure	Not applicable	Recruiting	King Edward Medical University	62	2026-07-16	2026-08-19
Imaging Acetadote Metabolism in Glioblastoma Acetadote - Glioblastoma, GBM	Early Phase 1	Recruiting	University of Texas Southwestern Medical Center	10	2026-06-18	2026-06-23
Muco-active Agent Use and Clinical Outcomes After Lung Cancer Diagnosis in Chronic Obstructive Pulmonary Disease Muco-active agents, No muco-active agent use - Lung Cancer (Diagnosis), Chronic Obstructive Pulmonary Disease (COPD)		Active not recruiting	Seoul National University	27000	2026-06-01	2026-07-21
PROlonged Corticosteroid Treatment or N-ACetylcysteine for Severe Alcoholic Hepatitis N-Acetylcysteine (NAC) Treatment, Prednisolone, Placebo of N-acetylcysteine - Alcoholic Hepatitis	Phase 3	Recruiting	University Hospital, Lille	477	2026-05-22	2026-06-01
Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBT N-Acetyl-Cysteine, Placebo - Ovarian Cancer, Cognitive Impairment	Phase 1 / Phase 2	Recruiting	University of California, Irvine	102	2026-05-21	2026-07-17
DMSO Dual-Route Therapy for Refractory Tinnitus in Long-COVID and Post-COVID-19 Vaccine Injury DMSO-based otic solution with betahistine, dexamethasone, and lidocaine, DMSO-based transdermal cream with levocarnitine and N-acetylcysteine - Tinnitus	Phase 2	Enrolling by invitation	Leading Edge Clinic	20	2026-05-15	2026-05-13
Effect of Acetylcysteine Inhalation on Incidence and Time to Develop Ventilator Associated Pneumonia in Critically Ill Mechanically Ventilated Patients Acetyl cysteine, Normal (0.9%) saline - Ventilation Acquired Pneumonia	Phase 4	Recruiting	Cairo University	80	2026-03-01	2026-07-10
Prefrontal Glutamatergic Modulation by NAC and MBCT for Depression in Youth N-acetylcysteine, Mindfulness-based cognitive therapy, Placebo - Mild Depression	Phase 3	Recruiting	University of Cincinnati	160	2026-02-26	2026-03-11
Antioxidant Supplementation and Muscle Recovery From DOMS in Trained Women Creatine Monohydrate, Omega 3 FA (Fish Oil), N-Acetyl Cysteine (NAC) - Delayed Onset Muscle Soreness, Exercise-induced Muscle Damage	Not applicable	Completed	Antonio Molina Lopez	60	2026-02-19	2026-10-16
Efficacy of Rifaximin With NAC in IBS-D rifaximin 66mg + N-acetylcysteine 560mg three times daily, RNIB21 containing rifaximin 132mg + N-acetylcysteine 560mg three times daily, Placebo - IBS (Irritable Bowel Syndrome), IBS-D (Diarrhea-predominant)	Phase 2	Recruiting	Mark Pimentel, MD	225	2026-02-04	2026-04-20
Effect of N-acetylcysteine as Adjunct Therapy on the Clinical Outcome of Neonatal Sepsis N-Acetyl Cysteine (NAC), Normal Saline - Neonatal Sepsis	Phase 3	Not yet recruiting	Ain Shams University	50	2026-02-01	2026-02-02

Showing 20 of 514. Sign in to see all of them.

Conditions studied

Renal Insufficiency, Chronic (15)  ·  COVID-19 (14)  ·  Pulmonary Disease, Chronic Obstructive (14)  ·  Acute Kidney Injury (13)  ·  Schizophrenia (12)  ·  Inflammation (11)  ·  Alcoholism (10)  ·  Kidney Failure, Chronic (10)  ·  Bipolar Disorder (9)  ·  Cocaine-Related Disorders (8)  ·  Liver Failure, Acute (8)  ·  Marijuana Abuse (8)  ·  Psychotic Disorders (8)  ·  Chemical and Drug Induced Liver Injury (7)  ·  Diabetes Mellitus (7)

Sponsors

Medical University of South Carolina (20)  ·  Ain Shams University (18)  ·  Yale University (10)  ·  Peking University People's Hospital (9)  ·  Stanford University (8)  ·  University of Minnesota (8)  ·  Assiut University (6)  ·  Baylor College of Medicine (6)  ·  Tanta University (6)  ·  University of California, San Francisco (6)  ·  Assaf-Harofeh Medical Center (5)  ·  Institute of Liver and Biliary Sciences, India (5)  ·  Massachusetts General Hospital (5)  ·  The First Affiliated Hospital of Soochow University (5)  ·  Cairo University (4)

Countries

United States (202)  ·  Egypt (43)  ·  Canada (20)  ·  Brazil (19)  ·  China (16)  ·  United Kingdom (12)  ·  Iran (11)  ·  Italy (11)  ·  Spain (11)  ·  Israel (10)  ·  Belgium (9)  ·  France (9)  ·  Germany (9)  ·  Netherlands (8)  ·  Taiwan (8)

Top investigators

Kevin M Gray, MD (6)  ·  Janet Wozniak, MD (4)  ·  Xiao-Jun Huang, MD (4)  ·  John Hegarty, PhD (3)  ·  Jon E Grant, MD, JD (3)  ·  Leonid S Feldman, MD (3)  ·  Antonio Hardan, MD (2)  ·  Daniel A Monti, MD, MBA (2)  ·  Dorothea Jenkins, MD (2)  ·  Edward A Neuwelt, MD (2)  ·  Gihyun Yoon, MD (2)  ·  Imre Noth, MD (2)  ·  John Fahy, M.D, M.Sc. (2)  ·  Jon E Grant, MD, JD, MPH (2)  ·  Lamia El Wakeel, Professor (2)

Results publications

PMID 37916745, PMID 34582562, PMID 23265409, PMID 23860343, PMID 37183883, PMID 39189858, PMID 10343249, PMID 10488881, PMID 10836917, PMID 10856474, PMID 10924859, PMID 11156645, PMID 11857360, PMID 12170403, PMID 1305308, PMID 14506405, PMID 14605526, PMID 1479177, PMID 15044883, PMID 15706734, PMID 15738894, PMID 15818423, PMID 15888773, PMID 16266222, PMID 16306520, PMID 16363316, PMID 16373736, PMID 16443707, PMID 16807414, PMID 16937471, PMID 16953900, PMID 17230616, PMID 17606664, PMID 18202091, PMID 18295688, PMID 18434903, PMID 18513531, PMID 18993042, PMID 19198022, PMID 19384218, PMID 19497091, PMID 19524577, PMID 19554195, PMID 19554657, PMID 19563648, PMID 19581567, PMID 19860915, PMID 20148732, PMID 20541301, PMID 20638463

NIH funding

K99HD101702 (2), U54NS065768 (2), 1RC1DA028279-01 (1), 1UG1EY033293 (1), 2009 (1), 2018 (1), 2019 (1), 2025 (1), F31NS108623 (1), I01CX000264 (1), K01DA039299 (1), K12DA000357 (1), K23AA025399 (1), P01HL128191 (1), P20GM109040 (1)